dimethylsynaptamide

Dimethylsynaptamide (also known as DMS or A8) is a synthetic, stable small-molecule analog of synaptamide (N-docosahexaenoylethanolamine), which is an endogenous metabolite of docosahexaenoic acid (DHA). It acts as a potent agonist of the adhesion G-protein coupled receptor 110 (GPR110, also known as ADGRF1). By binding to GPR110, dimethylsynaptamide activates the cAMP/PKA/CREB signaling pathway, promoting neurite outgrowth, synaptogenesis, and neuroprotection while suppressing neuroinflammation. Developed by the National Institutes of Health (NIH) in collaboration with other institutions, dimethylsynaptamide has demonstrated preclinical efficacy in animal models of multiple sclerosis (experimental autoimmune encephalomyelitis), traumatic brain injury, and optic nerve injury.

Other names

(4Z,7Z,10Z,13Z,16Z,19Z)-N-(2-hydroxy-2-methylpropyl) docosa-4,7,10,13,16,19-hexaenamideDMS